[go: up one dir, main page]

MX2022005888A - Metodos para tratar afecciones oculares. - Google Patents

Metodos para tratar afecciones oculares.

Info

Publication number
MX2022005888A
MX2022005888A MX2022005888A MX2022005888A MX2022005888A MX 2022005888 A MX2022005888 A MX 2022005888A MX 2022005888 A MX2022005888 A MX 2022005888A MX 2022005888 A MX2022005888 A MX 2022005888A MX 2022005888 A MX2022005888 A MX 2022005888A
Authority
MX
Mexico
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
MX2022005888A
Other languages
English (en)
Inventor
James Loudin
Kenneth J Mandell
Jr Douglas Michael Ackermann
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022005888(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of MX2022005888A publication Critical patent/MX2022005888A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)

Abstract

En la presente se describen métodos y formulaciones farmacéuticas para tratar afecciones oculares.
MX2022005888A 2014-10-20 2017-04-19 Metodos para tratar afecciones oculares. MX2022005888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07

Publications (1)

Publication Number Publication Date
MX2022005888A true MX2022005888A (es) 2022-06-14

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005064A MX392383B (es) 2014-10-20 2015-10-19 Metodos para tratar afecciones oculares.
MX2022005888A MX2022005888A (es) 2014-10-20 2017-04-19 Metodos para tratar afecciones oculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005064A MX392383B (es) 2014-10-20 2015-10-19 Metodos para tratar afecciones oculares.

Country Status (21)

Country Link
US (14) US9504645B2 (es)
EP (3) EP4413974A3 (es)
JP (3) JP6873906B2 (es)
KR (2) KR102511955B1 (es)
CN (3) CN111956803B (es)
AU (2) AU2015336216B2 (es)
BR (2) BR112017008097B1 (es)
CA (1) CA2965129C (es)
DK (2) DK3848028T5 (es)
EA (1) EA035335B1 (es)
ES (2) ES2986830T3 (es)
FI (1) FI3848028T3 (es)
IL (3) IL293188B2 (es)
MX (2) MX392383B (es)
MY (1) MY186870A (es)
PH (1) PH12017500602A1 (es)
PL (1) PL3848028T3 (es)
PT (2) PT3209295T (es)
SG (2) SG11201703135XA (es)
WO (1) WO2016064759A1 (es)
ZA (1) ZA201703467B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008097B1 (pt) 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN112638364A (zh) * 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
EP4142734B1 (en) 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
DE60209929T2 (de) 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
AU2005304034B2 (en) * 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
WO2006100075A2 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US20070093420A1 (en) 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
ES2713062T3 (es) 2005-09-27 2019-05-17 Tissuetech Inc Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
DK2114970T3 (da) * 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA3090738C (en) 2008-12-01 2023-06-13 Oyster Point Pharma, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CA2841416A1 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
KR20140027939A (ko) * 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제
JP6162705B2 (ja) * 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
EP2786142A4 (en) * 2011-11-30 2015-07-22 Diagnostear Ltd DIAGNOSIS OF THE DRY EYE
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
PT2968368T (pt) 2013-03-15 2017-11-15 Glia Llc Administração craniana de substâncias farmacêuticas
WO2014172693A2 (en) 2013-04-19 2014-10-23 Oculeve, Inc. Nasal stimulation devices and methods
BR112017008097B1 (pt) 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions

Also Published As

Publication number Publication date
IL293188B2 (en) 2025-06-01
PT3209295T (pt) 2021-02-05
IL293188B1 (en) 2025-02-01
US20230226054A1 (en) 2023-07-20
US20250275963A1 (en) 2025-09-04
US9504644B2 (en) 2016-11-29
BR112017008097A2 (pt) 2018-02-20
EA035335B1 (ru) 2020-05-28
PH12017500602A1 (en) 2017-09-04
CN111956650B (zh) 2024-06-04
US20200246336A1 (en) 2020-08-06
US11903942B2 (en) 2024-02-20
JP7257371B2 (ja) 2023-04-13
JP2017531044A (ja) 2017-10-19
KR20170086040A (ko) 2017-07-25
PL3848028T3 (pl) 2024-11-18
EP3209295B2 (en) 2023-12-06
CA2965129C (en) 2024-03-12
ES2848977T5 (es) 2024-06-06
CN111956803A (zh) 2020-11-20
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
MY186870A (en) 2021-08-26
US20240173318A1 (en) 2024-05-30
CN111956650A (zh) 2020-11-20
CA2965129A1 (en) 2016-04-28
US9597284B2 (en) 2017-03-21
JP6873906B2 (ja) 2021-05-19
IL318427A (en) 2025-03-01
US20230226053A1 (en) 2023-07-20
US11903943B2 (en) 2024-02-20
JP7502404B2 (ja) 2024-06-18
JP2023024574A (ja) 2023-02-16
CN107106542B (zh) 2020-05-08
US20160106744A1 (en) 2016-04-21
MX392383B (es) 2025-03-24
CN111956803B (zh) 2025-10-31
US20230226052A1 (en) 2023-07-20
SG11201703135XA (en) 2017-05-30
EP3209295B1 (en) 2020-12-09
US20250255865A1 (en) 2025-08-14
KR102601505B1 (ko) 2023-11-14
KR20230042144A (ko) 2023-03-27
BR122022025737B1 (pt) 2023-12-26
KR102511955B1 (ko) 2023-03-22
AU2020213351B2 (en) 2023-04-06
FI3848028T3 (fi) 2024-08-21
AU2015336216A1 (en) 2017-06-08
DK3848028T5 (da) 2025-01-20
US11903941B2 (en) 2024-02-20
ES2848977T3 (es) 2021-08-13
EP4413974A2 (en) 2024-08-14
AU2015336216B2 (en) 2020-05-21
PT3848028T (pt) 2024-09-20
CN107106542A (zh) 2017-08-29
US9532944B2 (en) 2017-01-03
US20170239244A1 (en) 2017-08-24
JP2021038250A (ja) 2021-03-11
AU2020213351A1 (en) 2020-08-27
US9504645B2 (en) 2016-11-29
WO2016064759A1 (en) 2016-04-28
EP3209295A1 (en) 2017-08-30
US10456396B2 (en) 2019-10-29
IL251769A0 (en) 2017-06-29
US20160106665A1 (en) 2016-04-21
MX2017005064A (es) 2018-02-23
ES2986830T3 (es) 2024-11-12
EP3848028B1 (en) 2024-05-29
DK3209295T3 (da) 2021-03-01
IL251769B (en) 2022-06-01
US20160106745A1 (en) 2016-04-21
DK3209295T4 (da) 2024-02-26
EP3848028A1 (en) 2021-07-14
US20250235449A1 (en) 2025-07-24
US11911380B2 (en) 2024-02-27
BR112017008097B1 (pt) 2023-03-28
SG10202011669PA (en) 2020-12-30
EP3209295A4 (en) 2018-05-23
ZA201703467B (en) 2023-12-20
EP4413974A3 (en) 2024-10-09
IL293188A (en) 2022-07-01
EA201790893A1 (ru) 2018-01-31
EP3848028B9 (en) 2024-10-16
US11224598B2 (en) 2022-01-18
DK3848028T3 (da) 2024-08-26

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
IL246791A0 (en) Compositions and methods for treating eye diseases
EP3224278A4 (en) Methods and formulations for treating vascular eye diseases
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
ZA201703467B (en) Methods of treating ocular conditions
ZA201807438B (en) Methods of treating ocular conditions
EP3191185A4 (en) Device for targeted treatment of dermastoses
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3213762A4 (en) Novel treatment of cornea using laminin
TW201613587A (en) Medical treatments based on anamorelin
EP3340974A4 (en) METHODS OF TREATING DISEASES
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
EP3253211A4 (en) Compositions and methods for treatment of edema
EP3134108A4 (en) Agents and methods of treatment
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
IL246667A0 (en) Compositions and methods for treatment of abnormal cell growth
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3206708A4 (en) Methods and compositions for the treatment of radiation-related disorders
EP3302382A4 (en) IMPLANT FOR THE TREATMENT OF OCULAR DISEASE
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations